- Home
- SPRO vs BHAC Comparison
SPRO vs BHAC Comparison
Compare SPRO & BHAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- BHAC
- Stock Information
- Founded
- SPRO 2013
- BHAC 2021
- Country
- SPRO United States
- BHAC United States
- Employees
- SPRO N/A
- BHAC N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- BHAC Blank Checks
- Sector
- SPRO Health Care
- BHAC Finance
- Exchange
- SPRO Nasdaq
- BHAC Nasdaq
- Market Cap
- SPRO 74.0M
- BHAC 74.1M
- IPO Year
- SPRO 2017
- BHAC 2021
- Fundamental
- Price
- SPRO $1.31
- BHAC $10.60
- Analyst Decision
- SPRO Strong Buy
- BHAC
- Analyst Count
- SPRO 3
- BHAC 0
- Target Price
- SPRO $7.00
- BHAC N/A
- AVG Volume (30 Days)
- SPRO 124.6K
- BHAC 6.8K
- Earning Date
- SPRO 08-05-2024
- BHAC 01-01-0001
- Dividend Yield
- SPRO N/A
- BHAC N/A
- EPS Growth
- SPRO N/A
- BHAC N/A
- EPS
- SPRO 0.33
- BHAC 0.16
- Revenue
- SPRO $118,459,000.00
- BHAC N/A
- Revenue This Year
- SPRO N/A
- BHAC N/A
- Revenue Next Year
- SPRO N/A
- BHAC N/A
- P/E Ratio
- SPRO $4.12
- BHAC $64.26
- Revenue Growth
- SPRO 118.43
- BHAC N/A
- 52 Week Low
- SPRO $0.99
- BHAC $10.11
- 52 Week High
- SPRO $1.89
- BHAC $12.80
- Technical
- Relative Strength Index (RSI)
- SPRO 51.95
- BHAC 36.86
- Support Level
- SPRO $1.32
- BHAC $10.11
- Resistance Level
- SPRO $1.37
- BHAC $10.73
- Average True Range (ATR)
- SPRO 0.05
- BHAC 0.08
- MACD
- SPRO 0.00
- BHAC -0.02
- Stochastic Oscillator
- SPRO 41.18
- BHAC 54.32
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About BHAC Focus Impact BH3 Acquisition Company
Focus Impact BH3 Acquisition Co is a blank check company.